by Market Overview:
Aptamers are short, single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules that bind to a specific target. They are generated through an in vitro selection process called SELEX (Systematic Evolution of Ligands by EXponential enrichment). Aptamers bind to their targets with high specificity and affinity. They play a vital role in biomarker discovery, therapeutics development, research and diagnostics applications.
Market key trends:
One of the key trends in the aptamers market is its increasing use in the development of therapeutics. Aptamers possess several advantages over traditional monoclonal antibodies such as low toxicity, high solubility, ease of in vitro selection and modification, and lower production costs. Due to these advantages, aptamers are increasingly being researched and developed as potential therapeutics for the treatment of various diseases like cancer, retinal diseases, thrombosis, and inflammation. For instance, Macugen (Pegaptanib sodium), an anti-VEGF RNA aptamer, was the first FDA approved aptamer drug for the treatment of age-related macular degeneration. Regulatory approvals and clinical research for aptamer-based drugs are expected to significantly drive the growth of the aptamers market during the forecast period.
The global Aptamers Market Share is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights
SWOT Analysis
Strength: Aptamers have high affinity and specificity for target molecules. They can be developed against a wide range of targets such as small molecules, proteins, nucleic acids, cells or tissues.
Weakness: Aptamers have short shelf life and issues with stability under physiological conditions. Development of aptamers requires special expertise and infrastructure.
Opportunity: Growing demand for targeted therapies and minimally-invasive diagnostic tools drive the research on aptamers. Aptamer-based technologies offer potential solutions for precision medicine applications.
Threats: Stringent regulatory processes and high development costs pose challenges for commercialization. Alternative approaches such as monoclonal antibodies are well established in the market.
Key Takeaways
The global aptamers market is expected to witness high growth, exhibiting CAGR of 18.% over the forecast period, due to increasing demand for targeted therapeutics and diagnostics. Aptamers enable development of highly specific tools for diagnostic, analytical and therapeutic applications.
Regional analysis: North America dominated the global aptamers market in 2023 and is expected to maintain its leading position during the forecast period. This is attributed to strong government funding to support research activities and growing uptake of advanced technologies among end users in the US and Canada. Asia Pacific region is anticipated to witness fastest growth rate owing to rising R&D investments, improving healthcare infrastructure and increasing focus on precision medicine in China and India.
Key players operating in the aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Major players are focusing on partnerships, collaborations and new product launches to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
